SVV-037

**SVV-037** is an investigational **armed oncolytic Seneca Valley virus construct** being developed by **Seneca Therapeutics** for cancer. It is based on the company\u2019s SVV platform, which uses **Seneca Valley virus** to preferentially infect **TEM8-expressing tumor cells**, and SVV-037 is specifically engineered to express the chemokine **CXCL-9** in the tumor microenvironment. The intended mechanism is to combine direct oncolytic activity of the viral backbone with localized **CXCL-9-mediated immune-cell recruitment**, thereby enhancing antitumor immune infiltration and activity in solid tumors or other neoplasms. Publicly available pipeline information indicates the program has remained **preclinical** and is being pursued as an **intravenous gene therapy/oncolytic virus** candidate for oncology.

Other names

SVV+ CXCL-9